Literature DB >> 20046113

Intensive care unit-acquired weakness: framing the topic.

Jean-Louis Vincent1, Michelle Norrenberg.   

Abstract

One of the many potential sequelae of intensive care is prolonged weakness, which can be associated with increased morbidity during the intensive care unit stay and long-term functional disability. Despite increased awareness of this complication in recent years, diagnosing intensive care unit-acquired weakness remains difficult and there are no specific therapies. Management, therefore, relies on limiting its short- and long-term effects. One method by which this may be achieved is to reduce sedative use and promote early mobilization and exercise.

Entities:  

Mesh:

Year:  2009        PMID: 20046113     DOI: 10.1097/CCM.0b013e3181b6f1e1

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

1.  Computed Tomography Evidence of Psoas Muscle Atrophy Without Concomitant Tendon Wasting in Early Sepsis.

Authors:  Carrie A Kubiak; Kavitha Ranganathan; Niki Matusko; Jon A Jacobson; Stewart C Wang; Pauline K Park; Benjamin L Levi
Journal:  J Surg Res       Date:  2018-10-11       Impact factor: 2.192

2.  Multimodal assessment of intensive care unit-acquired weakness in severe stroke patients.

Authors:  Berin Inan; Can Ebru Bekircan-Kurt; Zeynep Ergul-Ulger; Merve Yilmaz; Zeliha Gunnur Dikmen; Ethem Murat Arsava; Mehmet Akif Topcuoglu; Omur Caglar; Merve Basol; Ergun Karaagaoglu; Sevim Erdem-Ozdamar; Ersin Tan; Cagri Mesut Temucin
Journal:  Acta Neurol Belg       Date:  2022-07-06       Impact factor: 2.471

3.  GTS-21 attenuates loss of body mass, muscle mass, and function in rats having systemic inflammation with and without disuse atrophy.

Authors:  Stefan J Schaller; Michio Nagashima; Martin Schönfelder; Tomoki Sasakawa; Fabian Schulz; Mohammed A S Khan; William R Kem; Gerhard Schneider; Jürgen Schlegel; Heidrun Lewald; Manfred Blobner; J A Jeevendra Martyn
Journal:  Pflugers Arch       Date:  2018-07-13       Impact factor: 3.657

4.  Urea amidolyase (DUR1,2) contributes to virulence and kidney pathogenesis of Candida albicans.

Authors:  Dhammika H M L P Navarathna; Michail S Lionakis; Martin J Lizak; Jeeva Munasinghe; Kenneth W Nickerson; David D Roberts
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

Review 5.  Exercise rehabilitation following hospital discharge in survivors of critical illness: an integrative review.

Authors:  Bronwen Connolly; Linda Denehy; Stephen Brett; Doug Elliott; Nicholas Hart
Journal:  Crit Care       Date:  2012-06-20       Impact factor: 9.097

6.  Serodiversity of opsonic antibodies against Enterococcus faecalis--glycans of the cell wall revisited.

Authors:  Christian Theilacker; Zbigniew Kaczyński; Andrea Kropec; Irina Sava; Libin Ye; Anna Bychowska; Otto Holst; Johannes Huebner
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

7.  The role of inflammation in ICU-acquired weakness.

Authors:  Chris Winkelman
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

8.  Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock.

Authors:  Joerg C Schefold; Jeffrey Bierbrauer; Steffen Weber-Carstens
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

9.  Early mobilisation in intensive care units in Australia and Scotland: a prospective, observational cohort study examining mobilisation practises and barriers.

Authors:  Meg E Harrold; Lisa G Salisbury; Steve A Webb; Garry T Allison
Journal:  Crit Care       Date:  2015-09-14       Impact factor: 9.097

10.  Accumulation of pharmaceuticals, Enterococcus, and resistance genes in soils irrigated with wastewater for zero to 100 years in central Mexico.

Authors:  Philipp Dalkmann; Melanie Broszat; Christina Siebe; Elisha Willaschek; Tuerkan Sakinc; Johannes Huebner; Wulf Amelung; Elisabeth Grohmann; Jan Siemens
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.